Sugi Predict

Sugi Predict / Compounds / SCHEMBL372037

SCHEMBL372037

SCHEMBL372037

CC(C)(C)OC(=O)N1C[C@H]2CC(=O)C[C@H]2C1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.58
▸ DDB1 Q16531 1/20 0.45
▸ CRBN Q96SW2 1/20 0.45
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ LIPE Q05469 2/20 0.43
▸ GPR119 Q8TDV5 4/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPT P10636 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ NAMPT P43490 1/20 0.42
▸ HPGD P15428 1/20 0.41
▸ USP30 Q70CQ3 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22270526 1.00 NR1H2 (0.58) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL20566526 1.00 NR1H2 (0.58) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL13727442 1.00 NR1H2 (0.58) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL30988547 1.00 NR1H2 (0.58) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL903878 1.00 NR1H2 (0.58) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL5937854 0.89 NR1H2 (0.51) NR1H2GPR119KDM4EMAPTTHRB
SCHEMBL12324578 0.89 NR1H2 (0.51) NR1H2GPR119KDM4EMAPTTHRB
SCHEMBL5937862 0.89 NR1H2 (0.51) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL12323280 0.89 NR1H2 (0.51) NR1H2GPR119KDM4EMAPTTHRB
SCHEMBL6747266 0.89 NR1H2 (0.51) NR1H2DDB1CRBNUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119907789-A Preparation method of key intermediate of JAK kinase inhibitor 上海再启生物技术有限公司 2025-04-29 — — CN claimed
CN-119894868-A Synthesis method of key intermediate of JAK kinase inhibitor 上海再启生物技术有限公司 2025-04-25 — — CN claimed
CN-112679411-B Preparation method of chiral 5- (methylamino) hexahydrocyclopenta [ c ] pyrrole-2 (1H) -Boc methanesulfonate 上海再启生物技术有限公司 2022-04-01 — — CN claimed
CN-112679411-A Preparation method of chiral 5- (methylamino) hexahydrocyclopenta [ c ] pyrrole-2 (1H) -Boc methanesulfonate 上海再启生物技术有限公司 2021-04-20 — — CN claimed
US-20260132129-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER GENESIS THERAPEUTICS INC (US) 2026-05-14 — — US disclosed
WO-2026087613-A1 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS, PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2026-04-30 — — WO disclosed
EP-4087583-B1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-04-22 — — EP disclosed
US-12577234-B2 Antagonists of the muscarinic acetylcholine receptor M4 VANDERBILT UNIVERSITY (US) 2026-03-17 — — US disclosed
WO-2026050993-A1 PREPARATION METHOD FOR KEY INTERMEDIATE OF JAK KINASE INHIBITOR 上海再启生物技术有限公司 2026-03-12 — — WO disclosed
WO-2026050923-A1 METHOD FOR SYNTHESIZING KEY INTERMEDIATE OF JAK KINASE INHIBITOR 上海再启生物技术有限公司 2026-03-12 — — WO disclosed
EP-3810615-B1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-01-28 — — EP disclosed
EP-4673440-A1 INHIBITORS OF LRRK2 Vanderbilt University (US) 2026-01-07 — — EP disclosed
US-20100311747-A1 DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) 2010-12-09 — — US disclosed
EP-2246347-A1 DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) 2010-11-03 — — EP disclosed
EP-2205589-A2 C-MET PROTEIN KINASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2010-07-14 — — EP disclosed
WO-2009045992-A2 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-04-09 — — WO disclosed
WO-2009045992-A2 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-04-09 — — WO disclosed
US-7164024-B2 Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-16 — — US disclosed
US-20060287290-A1 Azabicyclic compounds are central nervous system active agents DART MICHAEL J 2006-12-21 — — US disclosed
EP-1386920-A1 BENZIMIDAZOLONE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-02-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132129-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER PIK3R4, PIK3R1, PIK3R5 NR1H2 201/4885DDB1 2127/4885CRBN 1269/4885
US-20100311747-A1 DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF DPP4, DPP8, DPP7 NR1H2 4484/4885DDB1 1651/4885CRBN 3695/4885
US-20060287290-A1 Azabicyclic compounds are central nervous system active agents ACHE, CHAT, CHRNA6 NR1H2 570/4885DDB1 1154/4885CRBN 2635/4885
US-12577234-B2 Antagonists of the muscarinic acetylcholine receptor M4 CHRM3, CHRM4, CHRM2 NR1H2 189/4885DDB1 3136/4885CRBN 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.